ANA podcasts & Webinars
ANA Investigates: Atrial Fibrillation after Stroke
Christoph Stretz MD,
Corresponding Author
Christoph Stretz MD
Department of Neurology & Neurosurgery, Brown University, Providence, Rhode Island, USA
Address correspondence to Christoph Stretz, MD, Department of Neurology, Brown University, Providence, RI, USA. E-mail: [email protected]
Search for more papers by this author Adeline L. Goss MD,
Adeline L. Goss MD
Division of Neurology, Department of Internal Medicine, Highland Hospital, Oakland, California, USA
Search for more papers by this author Michelle C. Johansen MD, PhD,
Michelle C. Johansen MD, PhD
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA
Search for more papers by this author Luciano A. Sposato MD, MBA,
Luciano A. Sposato MD, MBA
Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada
Search for more papers by this author
Christoph Stretz MD,
Corresponding Author
Christoph Stretz MD
Department of Neurology & Neurosurgery, Brown University, Providence, Rhode Island, USA
Address correspondence to Christoph Stretz, MD, Department of Neurology, Brown University, Providence, RI, USA. E-mail: [email protected]
Search for more papers by this author Adeline L. Goss MD,
Adeline L. Goss MD
Division of Neurology, Department of Internal Medicine, Highland Hospital, Oakland, California, USA
Search for more papers by this author Michelle C. Johansen MD, PhD,
Michelle C. Johansen MD, PhD
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA
Search for more papers by this author Luciano A. Sposato MD, MBA,
Luciano A. Sposato MD, MBA
Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada
Search for more papers by this author
First published: 14 February 2025
No abstract is available for this article.
Potential Conflicts of Interest
Dr. Sposato disclosed consulting fees and honoraria from Bayer, Boehringer Ingelheim, Pfizer, Gore, AstraZeneca, and Simcere.
References
- 1Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4: 816–861. https://doi.org/10.1016/j.hrthm.2007.04.005.
- 2Sposato LA, Field TS, Schnabel RB, et al. Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack. Lancet Neurol 2024; 23: 110–122. https://doi.org/10.1016/s1474-4422(23)00326-5.
- 3Sposato LA, Sur NB, Katan M, et al. Embolic stroke of undetermined source: new data and new controversies on cardiac monitoring and anticoagulation. Neurology 2024; 103:e209535. https://doi.org/10.1212/wnl.0000000000209535.
- 4Kirchhof P, Toennis T, Goette A, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023; 389: 1167–1179. https://doi.org/10.1056/NEJMoa2303062.
- 5Healey JS, Lopes RD, Granger CB, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024; 390: 107–117. https://doi.org/10.1056/NEJMoa2310234.
